Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Contingent Liabilities and Commitments (Details)

v3.23.1
Contingent Liabilities and Commitments (Details)
€ in Thousands
12 Months Ended
Dec. 31, 2022
EUR (€)
Contingent Liabilities and Commitments (Details) [Line Items]  
Commission Income Expense € 25
Annual royalties 10
Royalties in a total amount € 850
Royalty payments, percentage 10.00%
Patent agreement, description Royalties in a total amount of up to €850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) €50 thousand upon initiation of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III studies; and (iv) €500 thousand upon marketing approval by any regulatory authority.
Minimum [Member]  
Contingent Liabilities and Commitments (Details) [Line Items]  
Percentage of net sales 2.00%
Maximum [Member]  
Contingent Liabilities and Commitments (Details) [Line Items]  
Percentage of net sales (3.00%)